RBC Capital on Ocular Therapeutix (OCUL): Weakness a Buying Opportunity
Tweet Send to a Friend
RBC Capital analyst Lisa Walter reiterated an Outperform rating and $30.00 price target on Ocular Therapeutix (NASDAQ: OCUL).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
